JP2024520630A - ブルトン型チロシンキナーゼの阻害剤及びその使用方法 - Google Patents

ブルトン型チロシンキナーゼの阻害剤及びその使用方法 Download PDF

Info

Publication number
JP2024520630A
JP2024520630A JP2023574315A JP2023574315A JP2024520630A JP 2024520630 A JP2024520630 A JP 2024520630A JP 2023574315 A JP2023574315 A JP 2023574315A JP 2023574315 A JP2023574315 A JP 2023574315A JP 2024520630 A JP2024520630 A JP 2024520630A
Authority
JP
Japan
Prior art keywords
formula
compound
iii
alkyl
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520630A5 (enExample
Inventor
バラスブラマニアン，スリラム
コーネリッセン，イヴォ
グオ，ユエ
エイチ． レウ，ジョセリン
イー． パックマン，キャサリン
アレクサンダー パルマー，ジェイムス
フィリパール，ウルリーケ
ラオ，ナビン
エス． ティチェナー，マーク
ディー． ヴェナブル，ジェニファー
ジェイ．エム． ウィーナー，ジョン
ミャオ，シン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024520630A publication Critical patent/JP2024520630A/ja
Publication of JP2024520630A5 publication Critical patent/JP2024520630A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023574315A 2021-06-04 2022-06-02 ブルトン型チロシンキナーゼの阻害剤及びその使用方法 Pending JP2024520630A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
US63/196,843 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (2)

Publication Number Publication Date
JP2024520630A true JP2024520630A (ja) 2024-05-24
JP2024520630A5 JP2024520630A5 (enExample) 2025-05-28

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574315A Pending JP2024520630A (ja) 2021-06-04 2022-06-02 ブルトン型チロシンキナーゼの阻害剤及びその使用方法

Country Status (14)

Country Link
US (1) US12622910B2 (enExample)
EP (1) EP4346834A1 (enExample)
JP (1) JP2024520630A (enExample)
KR (1) KR20240019214A (enExample)
CN (1) CN117412753A (enExample)
AU (1) AU2022284369A1 (enExample)
BR (1) BR112023025459A2 (enExample)
CA (1) CA3220015A1 (enExample)
CL (2) CL2023003564A1 (enExample)
IL (1) IL308951A (enExample)
JO (1) JOP20230310A1 (enExample)
MX (1) MX2023014435A (enExample)
TW (1) TW202317127A (enExample)
WO (1) WO2022254371A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2018536686A (ja) * 2015-12-10 2018-12-13 ヤンセン ファーマシューティカ エヌ．ベー． ブルトン型チロシンキナーゼの阻害剤としての多環式化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US4886646A (en) 1988-03-23 1989-12-12 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Hanging drop crystal growth apparatus and method
US5096676A (en) 1989-01-27 1992-03-17 Mcpherson Alexander Crystal growing apparatus
US5130105A (en) 1990-10-23 1992-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Protein crystal growth tray assembly
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5400741A (en) 1993-05-21 1995-03-28 Medical Foundation Of Buffalo, Inc. Device for growing crystals
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
JP2015536446A (ja) 2012-10-11 2015-12-21 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤療法のためのコンパニオン診断
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2023522957A (ja) 2020-04-21 2023-06-01 フラッグシップ パイオニアリング， インコーポレイテッド 二機能性分子およびその使用方法
MX2024010134A (es) 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
JP2018536686A (ja) * 2015-12-10 2018-12-13 ヤンセン ファーマシューティカ エヌ．ベー． ブルトン型チロシンキナーゼの阻害剤としての多環式化合物
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUCAS, FABIENNE ET AL.: "Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies", TARGETED ONCOLOGY, vol. 14, no. 2, JPN6026022542, 2019, pages 125 - 138, ISSN: 0005875159 *
SAIDU, NATHANIEL EDWARD BENNETT ET AL.: "New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Dir", FRONTIERS IN IMMUNOLOGY, vol. 11, no. 578314, JPN6026022543, 2020, pages 1 - 19, ISSN: 0005875160 *

Also Published As

Publication number Publication date
WO2022254371A1 (en) 2022-12-08
US12622910B2 (en) 2026-05-12
CL2023003564A1 (es) 2024-06-21
EP4346834A1 (en) 2024-04-10
TW202317127A (zh) 2023-05-01
BR112023025459A2 (pt) 2024-02-27
IL308951A (en) 2024-01-01
US20230013755A1 (en) 2023-01-19
CN117412753A (zh) 2024-01-16
JOP20230310A1 (ar) 2023-11-29
MX2023014435A (es) 2024-03-08
AU2022284369A1 (en) 2024-01-25
CA3220015A1 (en) 2022-12-08
KR20240019214A (ko) 2024-02-14
CL2024002895A1 (es) 2025-02-14

Similar Documents

Publication Publication Date Title
AU2021240244B2 (en) Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor
US12622910B2 (en) Inhibitors of Bruton's tyrosine kinase and methods of their use
US20240238291A1 (en) Combinations for treatment of cancer
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
US12564590B2 (en) Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof
CN108024996A (zh) 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
WO2016106381A1 (en) Btk inhibitor combinations and dosing regimen
CA3223610A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
HK40107411A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
EA051432B1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
HK1249015B (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602